The Science of APS: Why the 'Two-Hit' Model Matters
At a Glance
The APS two-hit model explains that genetic immune-system susceptibility may create the first hit, while an event such as infection, surgery, pregnancy, or hormone exposure provides the second. Together they can activate clotting, although clots may occur without a clear trigger.
While many conditions are caused by a single “broken” gene, Antiphospholipid Syndrome (APS) is far more complex. It is best understood through the two-hit model or hypothesis. This theory offers a framework to explain why one person might have APS antibodies for decades and feel fine, while another person with the same antibodies experiences a life-altering blood clot. To understand this, we have to look at how your internal biology interacts with the world around you.
Hit 1: The Genetic Foundation
The “first hit” is your genetic blueprint. You are born with a susceptibility to APS, but genes alone do not cause the disease [1]. Scientists have identified several markers that act like “volume knobs,” turning up the sensitivity of your immune system.
- HLA Alleles: The most common genetic markers associated with APS are found in the HLA region, which helps your immune system distinguish your own cells from invaders. Markers like HLA-DR4 and HLA-DRw53 are frequently found in people with APS [2][3].
- Non-HLA Genes: Other genes, such as STAT4 and C1D, have also been linked to the condition [1]. These genes don’t “give” you APS; they simply make it more likely that your immune system will produce the specific antibodies that characterize the disease [2]. Note: These are research associations, not a validated genetic test that can predict your outcome, and routine genetic testing is not currently part of APS care.
The Bad Actor: Beta-2-Glycoprotein I
The primary “bad actor” in APS is often a group of antibodies that mistakenly target a protein called Beta-2-glycoprotein I (β2GPI) [4].
Normally, β2GPI circulates in your blood without causing trouble. However, in people with the genetic “first hit,” the immune system sees this protein as an enemy. When these antibodies bind to β2GPI, they latch onto the endothelium (the delicate inner lining of your blood vessels) [5]. This binding sends a signal to your body that the blood vessel is damaged, even when it isn’t, setting the stage for a clot to form [4].
Hit 2: The Environmental Trigger
If the genetic markers are the “dry brush” in a forest, the “second hit” is the match. This trigger is an environmental event that puts stress on the body, pushing the already-sensitive immune system into an overactive state [4][6].
Common “second hits” include:
- Infections: Even a common virus or bacterial infection can activate the immune response [7].
- Surgery or Trauma: Physical injury or the stress of a surgical procedure can trigger the clotting process [8].
- Pregnancy: The physiological changes of pregnancy and the postpartum period are significant stressors that can act as a trigger [9].
- Hormonal Changes: Starting estrogen-based birth control or hormone replacement therapy can sometimes serve as a second hit [6].
The Chain Reaction: Complement and Neutrophils
Once the second hit occurs, a rapid chain reaction begins. The antibodies don’t just sit on the vessel wall; they activate the complement system, a part of your immune system that “complements” the work of antibodies to clear out threats [9][5].
In APS, the complement system becomes hyper-activated, which in turn recruits neutrophils (a type of white blood cell). These neutrophils can release “nets” of DNA and proteins called Neutrophil Extracellular Traps (NETs). While NETs are meant to trap bacteria, in APS, they can actually trap blood cells and proteins, leading directly to the formation of a clot [4][9].
Understanding this two-hit model is empowering, but it is important to remember it is an incomplete model. Clots can sometimes occur without a clear trigger, and experiencing a clot is never a sign that you “failed” to manage your lifestyle.
Common questions in this guide
What does the two-hit model mean in antiphospholipid syndrome?
Does a family history of APS mean I will develop it?
What events can trigger a blood clot in APS?
How do APS antibodies cause blood clots?
Can genetic testing predict whether I will have an APS clot?
What should I discuss before surgery if I have APS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do I have the 'triple-positive' antibody profile, and what does that mean for my risk of a second hit?
- 2.Given my family history, which specific genetic markers (like HLA-DR4) were found if I was tested, and how do they influence my care?
- 3.What specific 'second hit' scenarios should I be most careful about—for example, long flights, certain surgeries, or specific infections?
- 4.How exactly do the antibodies in my blood interact with my blood vessel walls (endothelium)?
- 5.If I need surgery in the future, what is our 'hit prevention' plan for managing my blood thinners and infection risk?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (9)
- 1
Genetics of Antiphospholipid Syndrome.
Ortiz-Fernández L, Sawalha AH
Current rheumatology reports 2019; (21(12)):65 doi:10.1007/s11926-019-0869-y.
PMID: 31807905 - 2
Genetic aspects of the antiphospholipid syndrome: An update.
Sebastiani GD, Iuliano A, Cantarini L, Galeazzi M
Autoimmunity reviews 2016; (15(5)):433-9.
PMID: 26804759 - 3
Distribution of HLA-DRB1 Alleles in Patients With Antiphospholipid Syndrome and Their Association With Antiphospholipid Antibodies Presence and Damage Indexes.
Haladyj E, Stypinska B, Matusiewicz A, et al.
Journal of immunology research 2025; (2025()):2827348 doi:10.1155/jimr/2827348.
PMID: 40165867 - 4
Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.
Yang L, Guo R, Liu H, et al.
Frontiers in immunology 2025; (16()):1527554 doi:10.3389/fimmu.2025.1527554.
PMID: 40181965 - 5
An Update on Antiphospholipid Syndrome.
Xourgia E, Tektonidou MG
Current rheumatology reports 2022; (23(12)):84 doi:10.1007/s11926-021-01051-5.
PMID: 34985625 - 6
Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.
Okunlola AO, Ajao TO, Sabi M, et al.
Cureus 2024; (16(9)):e69730 doi:10.7759/cureus.69730.
PMID: 39429267 - 7
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.
Legault K, Schunemann H, Hillis C, et al.
Journal of thrombosis and haemostasis : JTH 2018; (16(8)):1656-1664 doi:10.1111/jth.14192.
PMID: 29978552 - 8
[2016 review on catastrophic antiphospholipid syndrome].
Costedoat-Chalumeau N, Coutte L, Le Guern V, et al.
Presse medicale (Paris, France : 1983) 2016; (45(12 Pt 1)):1084-1092 doi:10.1016/j.lpm.2016.07.023.
PMID: 27617783 - 9
Antiphospholipid Antibody Syndrome and Infertility.
Rodrigues VO, Soligo AGES, Pannain GD
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2019; (41(10)):621-627 doi:10.1055/s-0039-1697982.
PMID: 31658490
This page explains the two-hit model of antiphospholipid syndrome for informational purposes only and does not replace medical advice. Discuss your personal clotting risks, genetic questions, and any blood-thinner plan with your healthcare team.
Get notified when new evidence is published on familial antiphospholipid syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.